<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04518644</url>
  </required_header>
  <id_info>
    <org_study_id>CAMN107A2411</org_study_id>
    <nct_id>NCT04518644</nct_id>
  </id_info>
  <brief_title>Nilotininb, for Patients With CML-CP, CML-AP, or CML-BC</brief_title>
  <official_title>Managed Access Program to Provide Access to Nilotinib, for Patients With Imatinib-intolerant and/or Resistant Ph+ Chronic Myelogenous Leukemia (CML) in Chronic Phase, CML in Accelerated Phase, or CML in Blast Crisis Phase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this Cohort Treatment Plan is to allow access to Nilotinib for eligible&#xD;
      patients diagnosed with imatinib-intolerant and/or resistant Philadelphia Chromosome positive&#xD;
      (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Chronic Myelogenous Leukemia in&#xD;
      Accelerated Phase (CML-AP), or Chronic Myelogenous Leukemia in Blast Crisis Phase (CML-BC).&#xD;
      The patient's Treating Physician should follow the suggested treatment guidelines and comply&#xD;
      with all local health authority regulations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Chronic Myelogenous Leukemia (CML)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib</intervention_name>
    <description>The recommended dosing of nilotinib is 400 mg orally twice daily</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  One of the diagnoses listed below&#xD;
&#xD;
          -  Imatinib resistant Philadelphia chromosome positive CML in chronic phase and the&#xD;
             presence of the following criteria:&#xD;
&#xD;
          -  &lt; 15% blasts in peripheral blood or bone marrow&#xD;
&#xD;
          -  &lt; 30% blasts plus promyelocytes in peripheral blood and bone marrow&#xD;
&#xD;
          -  &lt; 20 % basophils in the peripheral blood&#xD;
&#xD;
          -  ≥ 100 x 109 / L (≥ 100,000/mm3) platelets&#xD;
&#xD;
          -  No evidence of extramedullary leukemic involvement, with the exception of liver or&#xD;
             spleen&#xD;
&#xD;
          -  Imatinib resistant Philadelphia chromosome positive CML in accelerated phase defined&#xD;
             as never in blast crisis before starting treatment with one or more of the following&#xD;
             criteria present within 4 weeks prior to beginning treatment:&#xD;
&#xD;
          -  ≥ 15% but &lt; 30% blasts in blood or bone marrow&#xD;
&#xD;
          -  ≥ 30% blasts plus promyelocytes in peripheral blood or bone marrow (providing that&#xD;
             &lt;30% blasts present in bone marrow)&#xD;
&#xD;
          -  peripheral basophils ≥ 20%&#xD;
&#xD;
          -  thrombocytopenia &lt; 100 x 109 / L unrelated to therapy&#xD;
&#xD;
          -  Imatinib resistant Philadelphia chromosome positive CML in blast crisis defined by any&#xD;
             of the following:&#xD;
&#xD;
          -  ≥ 30% blasts in peripheral blood or bone marrow aspirate&#xD;
&#xD;
          -  Appearance of extramedullary involvement other than hepatosplenomegaly proven by&#xD;
             biopsy (i.e., chloroma)&#xD;
&#xD;
          -  WHO Performance status of 0, 1, or 2&#xD;
&#xD;
          -  Imatinib must be discontinued at least 5 days prior to beginning nilotinib therapy&#xD;
&#xD;
          -  Normal organ, electrolyte and marrow functions as described below:&#xD;
&#xD;
          -  Potassium ≥ LLN (lower limit of normal) or corrected to within normal limits with&#xD;
             supplements prior to the first dose of investigational medication&#xD;
&#xD;
          -  Total calcium (corrected for serum albumin) ≥ LLN or correctable with supplements&#xD;
&#xD;
          -  Magnesium ≥ LLN or corrected to within normal limits with supplements prior to the&#xD;
             first dose of investigational medication&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 x ULN or ≤ 5.0 x ULN if considered due to tumor&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 x ULN unless considered due to tumor&#xD;
&#xD;
          -  Serum bilirubin ≤ 1.5 x ULN&#xD;
&#xD;
          -  Serum amylase and lipase ≤ 1.5 x ULN&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 x ULN or 24-hour creatinine clearance ≥ 50 ml/min (calculated&#xD;
             creatinine clearance using Cockcroft formula is acceptable)&#xD;
&#xD;
          -  Serum phosphorous ≥ LLN or corrected to within normal limits with supplements prior to&#xD;
             the first dose of nilotinib medication&#xD;
&#xD;
        Written patient informed consent must be obtained prior to start of treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of hypersensitivity to any drugs or metabolites of similar chemical classes as&#xD;
             nilotinib.&#xD;
&#xD;
          -  Previous treatment with any cytotoxic investigational drug ≤4 weeks prior to beginning&#xD;
             nilotinib. At least 2 weeks must have elapsed since the last dose of hormonal therapy&#xD;
             or any approved or investigational &quot;targeted&quot; kinase inhibitor agent with the&#xD;
             exception of imatinib which must be discontinued at least 5 days prior to beginning&#xD;
             therapy with nilotinib.&#xD;
&#xD;
          -  Impaired cardiac function, including any one of the following:&#xD;
&#xD;
          -  Inability to determine the QT interval on ECG&#xD;
&#xD;
          -  Complete left bundle branch block&#xD;
&#xD;
          -  Long QT syndrome or family history of long QT syndrome&#xD;
&#xD;
          -  History of or presence of significant ventricular or atrial tachyarrhythmias&#xD;
&#xD;
          -  Clinically significant resting brachycardia (&lt;50 beats per minute)&#xD;
&#xD;
          -  QTc &gt; 450 msec on baseline ECG (using the QTcF formula). If QTc &gt;450 and electrolytes&#xD;
             are not within normal ranges, electrolytes should be corrected and then the patient&#xD;
             rescreened for QTc&#xD;
&#xD;
          -  Myocardial infarction within 12 months prior to starting nilotinib&#xD;
&#xD;
          -  Other clinically significant heart disease (e.g. unstable angina, congestive heart&#xD;
             failure or uncontrolled hypertension).&#xD;
&#xD;
          -  Use of any medications that prolong the QT interval and CYP3A4 inhibitors if the&#xD;
             treatment cannot be either safely discontinued or switched to a different medication&#xD;
             prior to starting treatment. Please see http://crediblemeds.org/index.php for a&#xD;
             comprehensive list of agents that prolong the QT interval&#xD;
&#xD;
          -  Severe and/ or uncontrolled concurrent medical disease that in the opinion of the&#xD;
             treating physicians could cause unacceptable safety risks or compromise compliance&#xD;
             with the compassionate use treatment (e.g. impairment of gastrointestinal (GI)&#xD;
             function or GI disease that may significantly alter the absorption of nilotinib,&#xD;
             ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome,&#xD;
             or small bowel resection, uncontrolled diabetes, )&#xD;
&#xD;
          -  Patients who have undergone major surgery ≤ 2 weeks prior to Visit 1 or who have not&#xD;
             recovered from side effects of such surgery&#xD;
&#xD;
          -  Known Cytopathologically confirmed Central Nervous System infiltration.&#xD;
&#xD;
          -  Use of therapeutic warfarin.&#xD;
&#xD;
          -  Acute or chronic liver or renal disease considered unrelated to tumor.&#xD;
&#xD;
          -  Treatment with any hematopoietic colony-stimulating growth factors ≤ 1 week prior to&#xD;
             starting Nilotinib. Erythropoietin is allowed.&#xD;
&#xD;
          -  Patient who has not recovered from side effects of prior chemotherapy, immunotherapy,&#xD;
             other investigational drugs, wide field radiotherapy, or major surgery. Patient who&#xD;
             has received imatinib &lt; 5 days prior to AMN107 or has not recovered from side effects&#xD;
             of therapy. Hydroxyurea is permitted during the first 28 days of treatment (up to 5&#xD;
             g/day) for a maximum of 7 days.&#xD;
&#xD;
          -  Patient with a history of another primary malignancy that is currently clinically&#xD;
             significant or requires active intervention.&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a&#xD;
             female after conception and until the termination of gestation, confirmed by a&#xD;
             positive hCG laboratory test (&gt; 5 mIU/mL).&#xD;
&#xD;
        Pregnancy statements and contraception requirements:&#xD;
&#xD;
          -  In accordance with good medical practice, clinical programs, Treatment Plans, in this&#xD;
             case, should include measures that will minimize the possibility of fetal exposure to&#xD;
             the investigational drug. Therefore, precautions should be taken in programs including&#xD;
             women of childbearing potential. For these women, two criteria are given, one more and&#xD;
             one less restrictive. Less restrictive wording is suggested for drugs in late&#xD;
             development stage with complete negative repro toxicology data; in other cases, the&#xD;
             more restrictive wording should be used.&#xD;
&#xD;
          -  For programs in which pre-menarche females could potentially be included, any female&#xD;
             aged 8 years and above is to be treated as a woman of child-bearing potential, and&#xD;
             this part of the definition should be added to the exclusion statement.&#xD;
&#xD;
          -  If there are potential drug-drug interactions between hormonal contraceptives and the&#xD;
             treatment, the acceptable contraception method must be non-hormonal.&#xD;
&#xD;
          -  The patient Informed Consent for MAP participation must specify reproductive risks,&#xD;
             compliance with adequate contraception methods, and permission to seek information&#xD;
             regarding pregnancy outcome in case of an unintended pregnancy. In programs where&#xD;
             abstinence is an allowable form of birth control, patients must agree to refrain from&#xD;
             sexual activity.&#xD;
&#xD;
          -  Women of child-bearing potential, defined as all women physiologically capable of&#xD;
             becoming pregnant, including women whose career, lifestyle, or sexual orientation&#xD;
             precludes intercourse with a male partner and women whose partners have been&#xD;
             sterilized by vasectomy or other means, UNLESS they are using two birth control&#xD;
             methods. The two methods can be a double barrier method or a barrier method plus a&#xD;
             hormonal method.&#xD;
&#xD;
        Adequate barrier methods of contraception include: diaphragm, condom (by the partner),&#xD;
        intrauterine device (copper or hormonal), sponge or spermicide. Hormonal contraceptives&#xD;
        include any marketed contraceptive agent that includes an estrogen and/or a progestational&#xD;
        agent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+81337978748</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Auchenflower</city>
        <state>Queensland</state>
        <zip>4066</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4064</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vitoria</city>
        <state>Espirito Santo</state>
        <zip>29043-260</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Goiania</city>
        <state>Goias</state>
        <zip>74605-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>20.211-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jau</city>
        <state>SP</state>
        <zip>17210-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05651-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>20211-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salvador</city>
        <zip>40110-150</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Teresina</city>
        <zip>64001280</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nicosia</city>
        <zip>2029</zip>
        <country>Cyprus</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10153</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo city</city>
        <state>Hokkaido</state>
        <zip>060 8648</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chaingmai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Cyprus</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Poland</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 14, 2020</study_first_submitted>
  <study_first_submitted_qc>August 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2020</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nilotinib</keyword>
  <keyword>Imatinib-intolerant</keyword>
  <keyword>Imatinib resistant</keyword>
  <keyword>Philadelphia Chromosome positive</keyword>
  <keyword>Ph+</keyword>
  <keyword>Chronic Myelogenous Leukemia in Chronic Phase</keyword>
  <keyword>CML-CP</keyword>
  <keyword>Chronic Myelogenous Leukemia in Accelerated Phase</keyword>
  <keyword>CML-AP</keyword>
  <keyword>Chronic Myelogenous Leukemia in Blast Crisis Phase</keyword>
  <keyword>CML-BC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

